Coultreon Biopharma
PrivateLast Round
Series A
Apr 28, 2026
Total Funding Raised
$148.4M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Coultreon Biopharma operates in Healthcare & Life Sciences and is based in Leuven. Its latest recorded funding round was a Series A round in April 2026.
Coultreon Biopharma is a biotechnology company that develops therapies targeting clinically-validated pathways across immunology and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Coultreon Biopharma Comparables
Compare Coultreon Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sitryx | 79% | |
| Galapagos NV | 69% | |
| AbbVie | 67% |
For institutional investors. Book with your work email.
Coultreon Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 28, 2026 | ||||
| Seed | Apr 1, 2025 |
For institutional investors. Book with your work email.
Coultreon Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Balyasny Asset Management L.P. | Series A |
| Finchley Healthcare Ventures | Series A |
| Forbion | Series A |
| Novo Holdings | Series A |
| Galapagos NV | Series A, Seed |
| Longwood Fund | Series A |
| Samsara BioCapital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 4, 2026
Grew 36% QoQ, from 22 to 30 employees.
- Jun 26, 2026
Grew 36% QoQ, from 22 to 30 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 14, 2026
Coultreon Biopharma appoints Nate Massari as Chief Business Officer on Sep 14th '26 in Belgium to support the advancement of its COL-5671 SIK3 inhibitor and immunology therapies.
- hiresSep 14, 2026
Coultreon Biopharma appoints Nate Massari as Chief Business Officer to support the advancement of its SIK3 inhibitor COL-5671 and immunology therapies in Belgium on Sep 14th '26.
- hiresAug 18, 2026
Coultreon Biopharma appoints Prista Charuworn as Chief Medical Officer to support the clinical development of COL-5671 and its progression into Phase II development.
- hiresAug 18, 2026
In Belgium on Aug 18th '26, Coultreon Biopharma appoints Prista Charuworn, MD as Chief Medical Officer as it prepares for clinical studies in ulcerative colitis and psoriasis.
For institutional investors. Book with your work email.
Coultreon Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Coultreon Biopharma's valuation, stock price, and market status.
Is Coultreon Biopharma a public or private company?
Coultreon Biopharma is a private company.
What is the current stock price of Coultreon Biopharma?
Coultreon Biopharma is a private company, so its shares have no public market price. Caplight tracks Coultreon Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Coultreon Biopharma worth (valuation)?
Valuation information for Coultreon Biopharma is not publicly available.
Can I buy Coultreon Biopharma stock?
Coultreon Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Coultreon Biopharma's last funding round?
Coultreon Biopharma's most recent funding round was Series A on April 28, 2026.
Who are the main investors in Coultreon Biopharma?
Key investors in Coultreon Biopharma include Forbion, Novo Holdings, Galapagos NV, Sofinnova Investments.
Will Coultreon Biopharma IPO soon?
No public IPO plans have been announced for Coultreon Biopharma.
How can I track Coultreon Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in Coultreon Biopharma's shares on secondary markets.